MedTrace Logo

Evaluation of Effects of Multiple Dose Regimens of CHF 5074 on Potential Biomarkers of Neurodegeneration in Subjects With Mild Cognitive Impairment

NCT01723670 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2015-02-10

No results posted yet for this study

Summary

To evaluate the effects of multiple dose regimens of CHF 5074 administered once per day up to 2 years on potential biomarkers of neurodegeneration in subjects with mild cognitive impairment.

Conditions

Interventions

DRUG

CHF 5074 1x

oral tablet, 1x, once a day for 24 months

DRUG

CHF 5074 2x

oral tablet, 2x, once a day for 24 months

DRUG

Placebo

oral tablet,once a day for 24 months

Sponsors & Collaborators

  • CERESPIR

    lead INDUSTRY

Principal Investigators

  • Joel S Ross, MD · Memory Enhancement Center of America

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2016-03-31
Completion
2016-03-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01723670 on ClinicalTrials.gov